Navigation Links
Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance
Date:9/3/2014

NORTH CHICAGO, Ill., Sept. 3, 2014 /PRNewswire/ -- Following the announcement of the collaboration agreements with Calico Life Sciences LLC (Calico) and Infinity Pharmaceuticals Inc (Infinity), AbbVie is amending its earnings guidance on a GAAP basis for the year ending December 31, 2014 and the third quarter ending September 30, 2014 as follows:

Revised Full-Year 2014 GAAP guidance:

Excluding the potential impact of the transaction with Shire, AbbVie is reducing its full year 2014 earnings-per-share guidance range on a GAAP basis to $2.11 to $2.21 after reflecting a reduction of $0.47 per share in relation to the upfront investment as part of the collaboration agreement with Calico and a reduction of $0.11 per share in relation to the upfront investment in the Infinity collaboration.  The full amount of both investments will be treated as a specified expense in 2014.

In addition, excluding the potential impact of the transaction with Shire, AbbVie is confirming its adjusted earnings-per-share guidance for the full-year 2014 of $3.06 to $3.16.

AbbVie's 2014 outlook continues to exclude any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy.

Revised Third-Quarter 2014 GAAP guidance:

Excluding the potential impact of the transaction with Shire, AbbVie is also reducing its Q3 2014 earnings-per-share guidance range on a GAAP basis to $0.41 to $0.43 after reflecting the reduction of $0.27 per share in relation to the initial commitment of the upfront investments in Q3 as stated above.

In addition, excluding the potential impact of the transaction with Shire, AbbVie is confirming its adjusted earnings-per-share guidance for the third quarter 2014 of $0.77 to $0.79, which also continues to exclude any potential revenue from the expected 2014 U.S. launch of its hepatitis C (HCV) therapy.

Collaboratio
'/>"/>

SOURCE AbbVie
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. International Probiotics Association Excited To Learn The FDA Has Decided To Issue A New, Revised NDI Draft Guidance
2. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
3. Preliminary Figures for 2011: Sartorius Grows at Double-Digit Rates and Boosts Operating Earnings by More Than 30%
4. Bacterin International Holdings, Inc. Schedules Fourth Quarter 2011 Financial Earnings Conference Call
5. WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
6. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
7. Haemonetics Reports First Quarter Fiscal 2013 Results, Completes Acquisition of Palls Transfusion Medicine Business, Affirms Fiscal 2013 Earnings Guidance, Provides Preliminary Outlook for Fiscal 2014 and Announces Share Repurchase
8. Perrigo Reports Record Fourth Quarter and Fiscal Year Revenue, Earnings and Cash Flow From Operations
9. Cambrex Reschedules Third Quarter 2012 Financial Results and Earnings Call Date to November 5, 2012
10. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
11. Zynga, Inc. Fourth-Quarter Earnings and Sales Topped Wall Street Estimates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... Global Stem Cells Group subsidiary Adimarket has been ... for the regeneration and repair of human organs and tissues. ... ambitious expansion plans in Latin America, a commitment made to ... and stem cell therapies. , Bioquark Inc. ... ability to alter the regulatory state of human tissues and ...
(Date:6/2/2015)... June 2, 2015 Meet ARGUS, ... Scanner. Scan & Read People. Analyze emotions and predict ... Concepts, including the very first Responsive-RPG: "The Eye: Genesis". ... , , , , https://www.youtube.com/watch?v=B1ZEtAZ2Yf8 ... truly affect your inner feelings - and those of ...
(Date:6/2/2015)... 02, 2015 “Stem Cell Therapy to help ... and it is used often as an adjunct to surgery ... are not yet aware or comfortable enough with the techniques ... most often reserved for the last resort cases - when ... barely lift a paw to get around. It is an ...
(Date:6/2/2015)... 2015 /PRNewswire/ -- China Cord Blood Corporation (NYSE: CO ) ... leading provider of cord blood collection, laboratory testing, ... announced that the Special Committee of the Company,s board of ... ( China ) Limited as its independent financial ... its United States legal counsel and ...
Breaking Biology Technology:Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 2Adimarket Named Latin American Distributor for Bioquark Biologic Products for the Regeneration and Repair of Human Organs and Tissue with Stem Cells 3ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 2ARGUS - The World's First Inner Emotion Scanner Launches on KickStarter 3VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 2VetStem Biopharma, Proudly Announces a New Long Term Partnership with VCA West Los Angeles in Support of Stem Cell Therapy Training and Clinical Opportunities. 3China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 2China Cord Blood Corporation's Special Committee Appoints Independent Financial Advisor and Legal Counsel to Evaluate Non-binding "Going Private" Proposal 3
... Inc. (OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company ... its financial results for the fourth quarter and year ... recent operational highlights for calendar year 2009 to date.GeoVax ... quarter ended December 31, 2008, as compared to a ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced that it ... North America to its most advanced BiTE antibody candidate, ... conducting a phase 2 clinical trial with blinatumomab for ...
... Production Efficiency and Reliability for New Shire Human Genetic ... HON ) today announced it will help ... development capabilities for creating life-saving medications. Shire Human Genetic ... will use several Honeywell solutions - including Experion(R) ...
Cached Biology Technology:GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 2GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 3GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 4GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 5GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 6GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 7GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 8GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 9GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 10GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 2Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 3Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 4Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 5Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 6Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 7Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 8Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 9Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 10Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 11Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008 12Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 2Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 3Honeywell Technology Selected to Control Manufacturing Processes at Major U.S. Biotech Site 4
(Date:5/11/2015)... Curemark LLC, a privately held drug research ... Phase III double blind, randomized, placebo-controlled clinical trial to ... all children ages 3-8 with Autism. Previously, Curemark announced ... blinded clinical trial for CM-AT in children ages 3-8 ... enzyme chymotrypsin. This new trial will help determine whether ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
(Date:4/27/2015)... more than four decades, AUVSI,s Unmanned Systems ... event for the unmanned land, sea, and air industries. ... local, national, or trade news organization interested in gathering ... applications of unmanned technologies. The conference will explore the ... and how it will soon impact the lives of ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5
... June 2009 Elsevier, the leading publisher of scientific, ... the highlights of its journal impact factor performance in ... factors (IF) increase from 2007 to 2008. According to ... journals took the #1 position in 51 categories (of ...
... 2008 Olympic Games, world record times of the men,s 100m ... and technological advances. Imagine if this improvement could be achieved ... Research Institute of Wildlife Ecology in Austria have managed to ... high in polyunsaturated fatty acids. Polyunsaturated fatty acids are ...
... a changing climate depends on the nutritional value and yield ... Australia have found an increase in toxic compounds, a decrease ... under high CO 2 and drought conditions. ... 29 June 2009 at the Society for Experimental Biology Annual ...
Cached Biology News:Elsevier announces 2008 journal impact factor highlights 2Elsevier announces 2008 journal impact factor highlights 3Mice run faster on high-grade oil 2
...
... Immunoperoxidase Secondary Detection System uses biotin-avidin-HRP complexed ... in the Primary Antibody. The primary antibody ... specimen. Any excess antibody is removed by ... to biotin) is added and will react ...
... Designed specifically for high ... cells. Low toxicity reagent proven ... wide range of cell types. ... than 95% of target gene ...
... Powerful exact mass measurements in ... orthogonal electrospray time-of-flight mass spectrometer (ESI-oa-TOF) ... machine in a format, which fits ... a mass resolution exceeding 10,000 FWHM ...
Biology Products: